Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RMX 1002

Drug Profile

RMX 1002

Alternative Names: RMX-1002

Latest Information Update: 04 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RMX biopharma
  • Developer HaiHe Biopharma; Ningbo NewBay Medical Technology; ShangHai HaiHe Pharmaceutical
  • Class Analgesics; Antineoplastics; Antirheumatics
  • Mechanism of Action Prostaglandin E EP4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pain
  • Phase I Arthritis; Familial adenomatous polyposis; Solid tumours

Most Recent Events

  • 18 Feb 2019 Haihe Pharmaceutical completes a phase I trial in Healthy volunteers in China, prior to February 2019 (HaiHe Biopharma pipeline, February 2019) .
  • 18 Feb 2019 Haihe Pharmaceutical completes a phase II trial for Pain in USA, prior to February 2019 (HaiHe Biopharma pipeline, February 2019) (9260757.
  • 12 Mar 2018 Phase-I clinical trials in Arthritis (In volunteers) in China (PO) (ChiCTR1800015060 )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top